Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | PPARD | Q03181 | 4/20 | 0.35 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475165 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL9355458 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL5373640 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL10887338 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL131065 | 1.00 | — | — | |
| SCHEMBL2166748 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL17022758 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL1241395 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL2167944 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL28258856 | 1.00 | PAOX (0.56) | PAOXALDH1A1ACHELMNASLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243805-B1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | NIPPON KAYAKU KK (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-7985287-B2 | Anthrapyridone compound or a salt thereof, magenta ink composition containing the anthrapyridone compound and colored product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20100291360-A1 | Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2243805-A1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | Nippon Kayaku Kabushiki Kaisha (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291360-A1 | Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product | MLLT3, MLLT1, H1-3 | PAOX 3852/4885ALDH1A1 1777/4885ACHE 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.